Article Text

Download PDFPDF
Letter to the editor
ERG expression in chondrogenic bone and soft tissue tumours: importance of antibody clone. Comment on Shon et al (2015)
  1. David Creytens
  1. Correspondence to Dr David Creytens, Department of Pathology, Ghent University Hospital, De Pintelaan 185, Ghent 9000, Belgium; david.creytens{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

I have read with great interest the paper of Shon et al1 demonstrating ERG expression in chondrogenic bone and soft tissue tumours, using an ERG monoclonal antibody against the N-terminus of this molecule (9FY, 1:50-1:100, BioCare). Based on the recent publication of Stockman et al2 showing that ERG antibodies directed against the C-terminus are less likely to label epithelioid sarcoma compared with those directed against the N-terminus, I prefer the anti-C-terminus ERG monoclonal antibody (EPR3864(2), 1:2000, Epitomics) instead of the anti-N-terminus ERG monoclonal antibody as relatively specific diagnostic marker of endothelial differentiation and as marker for Ewing sarcomas with EWSR1-ERG rearrangement.3 …

View Full Text


  • Contributors DC: data and result analysis, manuscript writing.

  • Competing interests None declared.

  • Ethics approval Ghent University Hospital.

  • Provenance and peer review Not commissioned; internally peer reviewed.